Trial: 201901148

A phase II study of inotuzumab ozogamicin followed by blinatumomab for Ph-negative, CD22-positive B-lineage acute lymphoblastic leukemia in newly diagnosed older adults or adults with relapsed or refractory disease

Phase

II

Principal Investigator

Uy, Geoffrey

Disease Site

Lymphoid Leukemia

Learn more about this study at: clinicaltrials.gov